- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Patent holdings for IPC class C07D 211/14
Total number of patents in this class: 400
10-year publication summary
|
26
|
27
|
22
|
26
|
30
|
24
|
29
|
26
|
31
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Nocion Therapeutics, Inc. | 51 |
9 |
| Bristol-myers Squibb Company | 4742 |
7 |
| Incyte Corporation | 1071 |
7 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3304 |
7 |
| Centre National de La Recherche Scientifique | 11023 |
6 |
| Incyte Holdings Corporation | 624 |
6 |
| Massachusetts Institute of Technology | 10251 |
5 |
| BASF SE | 21303 |
4 |
| Janssen Pharmaceutica N.V. | 3168 |
4 |
| Immunomet Therapeutics Inc. | 31 |
4 |
| Toyama Chemical Co., Ltd. | 88 |
4 |
| Anji Pharmaceuticals Inc. | 31 |
4 |
| Etherna Immunotherapies NV | 66 |
4 |
| Vividion Therapeutics, Inc. | 43 |
4 |
| Grey Wolf Therapeutics Limited | 17 |
4 |
| Cassava Science, Inc. | 14 |
4 |
| Chevron U.S.A. Inc. | 4140 |
3 |
| JSR Corporation | 2554 |
3 |
| Chong Kun Dang Pharmaceutical Corp. | 250 |
3 |
| Electrophoretics Limited | 84 |
3 |
| Other owners | 305 |